Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Adamas Pharmaceuticals

Request full access

Create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent…

Emeryville, United StatesFounded 2000Biotech & Life Sciences

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. was a specialty pharmaceutical company focused on developing and commercializing therapies for chronic neurologic disorders. Founded in 2000 by Greg Went, Ph.D., under the name NeuroMolecular, Inc., the company aimed to improve the lives of patients affected by central nervous system (CNS) conditions. The company's strategy revolved around enhancing the pharmacokinetic profiles of already approved drugs to create new therapeutic options. A significant milestone for Adamas was the U.S. Food and Drug Administration (FDA) approval of its lead product, GOCOVRI® (amantadine) extended-release capsules, on August 24, 2017. This marked the first and only medication specifically approved for the treatment of dyskinesia in Parkinson's disease patients receiving levodopa-based therapy.

The company's primary market was the central nervous system therapeutic area, specifically targeting patients with Parkinson's disease. Its business model centered on the development and commercialization of its proprietary drugs. Revenue was generated from the sales of its approved products. In a strategic move to expand its portfolio, Adamas acquired OSMOLEX ER® (amantadine) extended-release tablets from Osmotica Pharmaceuticals in January 2021. OSMOLEX ER is also approved for treating Parkinson's disease and drug-induced extrapyramidal reactions. This acquisition complemented its existing product line, providing physicians with multiple amantadine-based treatment options.

GOCOVRI, the company's cornerstone product, is an extended-release capsule taken once daily at bedtime. Its design ensures that drug levels are highest during the day, when symptoms like involuntary movements (dyskinesia) and "off" periods—when medication isn't working optimally—are most problematic. In February 2021, the FDA expanded GOCOVRI's approval to include use as an adjunctive treatment for "off" episodes in Parkinson's patients, making it the only drug approved to treat both motor complications. Following a period of growth and key product approvals, Adamas Pharmaceuticals was acquired by Supernus Pharmaceuticals, Inc. The definitive agreement was announced in October 2021 and the acquisition was completed in November 2021 for approximately $400 million in cash, plus potential future payments based on sales milestones. This acquisition allowed Supernus to strengthen its own CNS portfolio and diversify its revenue streams.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2014
Employees
44
Open positions
None listed
Dealroom signal
61.0/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Neurology, Epilepsy, Biotech and Pharma, Hard Tech, Became Thoroughbred as Subsidiary, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Oct 2021 $400M $400M Supernus Pharmaceuticals —
POST IPO EQUITYOther financing Mar 2021 $59M — Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Adamas Pharmaceuticals website traffic

Latest recorded traffic for Adamas Pharmaceuticals is 40 monthly website visits, down 78.9% over the last three months. Adamas Pharmaceuticals's team declined 2.2% over the past year.

Latest monthly visits40 3-month web change-78.9% 1-year team growth-2.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Adamas Pharmaceuticals in the Emeryville ecosystem

Live from Dealroom

The Adamas Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Mohr Davidow Ventures

Series B and later3 investors entered at this stage

Other known investors1 additional known investor

  • Supernus Pharmaceuticals
Team profiled 25 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Adamas Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.